glucagon is the most under-discussed thing in c/scamalerts
Something I noticed reading old threads that I have not seen said out loud. The advice on hepatic fat in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers…
Mechanistically the bit that matters is glucagon. It explains most of the early profile and a decent chunk of the outcome.
the MASH indication changes the risk calculus
That is net peptide content, not purity. Different number, different meaning.
phase 8 data is interesting, phase 25 will be different
You have restated the marketing copy. What is the actual substance here.
the heart rate signal is real in the data